Australian Pharmaceutical Industries Limited chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 8.05
Dividend & Yield0.04$ (2.52%)
Beta 0.12
Market capitalization 662.62M
Operating cash flow 81.75M
ESG Scores unknown

Company description

Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails health and beauty products to consumers through a network of Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores in Australia; sells beauty products through Clear Skincare network of clinics in Australia and New Zealand; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and non-invasive aesthetic beauty services. The company was founded in 1910 and is based in Camberwell, Australia.

Sector: Healthcare - Industry: Medical Distribution

Financial data

Financial Statements

Cashflow Statement 2017-08-31 2018-08-31 2019-08-31 2020-08-31
Change To Liabilities 4.66M -37.6M 7.01M -87.21M
Total Cashflows From Investing Activities -27.78M -82.31M -116.54M 51.13M
Net Borrowings -18.8M 59.29M 135.44M -219.14M
Total Cash From Financing Activities -53.09M 24.83M 97.27M -238.85M
Change To Operating Activities -6.02M 896k 532k 633k
Issuance Of Stock
Net Income 52.37M 48.06M 55.11M -8.39M
Change In Cash 14.29M -3.83M -7.71M 27.82M
Effect Of Exchange Rate -333k -3k -53k 29k
Total Cash From Operating Activities 95.48M 53.65M 11.61M 215.51M
Depreciation 17.04M 16.77M 17.52M 74.25M
Change To Account Receivables -2.31M 19.87M -34.88M 155.04M
Other Cashflows From Financing Activities
Change To Netincome 3.73M -9.87M -27.19M 22.86M
Capital Expenditures -28.29M -25.7M -35.7M -39.99M

Income Statement 2017-08-31 2018-08-31 2019-08-31 2020-08-31
Research Development
Income Before Tax 76.41M 70.03M 73.74M -14.65M
Net Income 52.37M 48.06M 55.11M -8.39M
Selling General Administrative 410.31M 423.2M 451.78M 435.39M
Gross Profit 493.63M 496.71M 518.3M 480.47M
Ebit 83.31M 73.51M 84.56M 52.56M
Operating Income 83.31M 73.51M 84.56M 52.56M
Interest Expense -8.3M -7.84M -12.6M -13.05M
Income Tax Expense 24.04M 21.82M 17.16M -6.71M
Total Revenue 4.06B 4.03B 4.01B 4.02B
Cost Of Revenue 3.57B 3.53B 3.49B 3.54B
Total Other Income ExpenseNet -6.9M -3.48M -10.81M -67.21M
Net Income From Continuing Ops 52.37M 48.2M 56.58M -7.94M
Net Income Applicable To Common Shares 52.37M 48.06M 55.11M -8.39M

Balance Sheet Statement 2017-08-31 2018-08-31 2019-08-31 2020-08-31
Total Liabilities 896.83M 1.01B 1.15B 1.09B
Total Stockholder Equity 554.25M 508.78M 501.26M 453.9M
Other Current Liabilities 24.81M 15.38M 15.12M 19.15M
Total Assets 1.45B 1.52B 1.66B 1.54B
Common Stock 566.46M 566.46M 566.46M 566.46M
Other Current Assets
Retained Earnings -18.51M -4.85M -11.19M -54.14M
Treasury Stock 6.29M -52.82M -54.01M -58.42M
Cash 39.78M 35.95M 30.18M 60.71M
Total Current Liabilities 851.03M 817.67M 887.48M 832.68M
Other Stockholder Equity 6.29M -52.82M -54.01M -58.42M
Property, Plant, and Equipment 95.28M 101.02M 107.13M 234.9M
Total Current Assets 1.12B 1.09B 1.1B 973.32M
Net Tangible Assets 360.94M 226.28M 200.34M 186.45M
Net Receivables 681.62M 654.66M 657.93M 544.43M
Accounts Payable 804.47M 778M 790.27M 741.95M


Insider Transactions

Here are the insider transactions of stock shares related to Australian Pharmaceutical Industries Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Macdonald (Jennifer)Purchase at price 0.75 per share.D2020-12-14Director (Non-Executive)25k
Smith (Mark Graham)D2020-09-04Former415k
Mendo (Peter)D2020-08-31Chief Financial Officer11.94k
Millner (Robert Dobson)D2020-07-09Former1.76M
Smith (Mark Graham)Purchase at price 0.66 per share.D2020-04-24Non Executive Chairman40k
Macdonald (Jennifer)Purchase at price 0.64 per share.D2020-04-23Director (Non-Executive)15k
Smith (Mark Graham)Purchase at price 0.87 per share.D2020-02-03Non Executive Chairman30k
Smith (Mark Graham)Purchase at price 0.91 per share.D2019-12-20Non Executive Chairman40k
Vincent (Richard)D2019-11-12Chief Executive Officer35.47k
Smith (Mark Graham)Purchase at price 0.87 per share.D2019-05-16Non Executive Chairman5k
Smith (Mark Graham)Purchase at price 0.92 per share.D2019-05-09Non Executive Chairman6.67k
Smith (Mark Graham)Purchase at price 0.92 per share.D2019-05-08Non Executive Chairman3.33k
Smith (Mark Graham)Purchase at price 1.03 per share.D2019-04-18Non Executive Chairman10k
Smith (Mark Graham)Purchase at price 0.94 per share.D2019-01-30Non Executive Chairman10k
Smith (Mark Graham)Purchase at price 0.98 per share.D2019-01-25Non Executive Chairman30k
Gunderson-Briggs (Kenneth William)Purchase at price 1.06 per share.D2018-12-14Director (Independent)10k
Smith (Mark Graham)Purchase at price 1.09 per share.D2018-12-14Non Executive Chairman70k
Vincent (Richard)D2018-11-07Chief Executive Officer17.08k
Smith (Mark Graham)Purchase at price 1.11 per share.D2018-02-06Non Executive Chairman35.55k
Gunderson-Briggs (Kenneth William)Other at price 1.17 per share.D2018-01-29Director (Independent)10k
Macdonald (Jennifer)Other at price 1.16 per share.D2018-01-25Director (Non-Executive)35k
Smith (Mark Graham)Purchase at price 1.16 per share.D2018-01-25Non Executive Chairman34.45k
Robinson (Peter Raymond)D2018-01-24Former238.83k
Smith (Mark Graham)Purchase at price 1.11 per share.D2017-11-23Non Executive Chairman10k
Smith (Mark Graham)Purchase at price 1.15 per share.D2017-11-16Non Executive Chairman5.47k
Smith (Mark Graham)Purchase at price 1.14 per share.D2017-11-14Non Executive Chairman24.53k
Vincent (Richard)D2017-11-03Chief Executive Officer283.84k
Smith (Mark Graham)Purchase at price 1.18 per share.D2017-10-30Non Executive Chairman30k
Smith (Mark Graham)Purchase at price 1.21 per share.D2017-10-25Non Executive Chairman30k
Gunderson-Briggs (Kenneth William)Purchase at price 1.43 per share.D2017-06-15Director (Independent)10k
Vincent (Richard)D2017-02-15Chief Executive Officer64.18k
Holley (Esther Carol)D2017-01-25Retired16.67k
Millner (Robert Dobson)Purchase at price 1.43 per share.D2016-10-28Director (Non-Executive)150k
Roche (Stephen Patrick)D2016-10-27Chief Executive Officer268.01k
Millner (Robert Dobson)Purchase at price 1.46 per share.D2016-04-22Director (Non-Executive)150.62k
Millner (Robert Dobson)Purchase at price 1.27 per share.D2015-04-24Director (Non-Executive)100k
Millner (Robert Dobson)Purchase at price 0.71 per share.D2015-01-30Director (Non-Executive)100k
Millner (Robert Dobson)Purchase at price 0.69 per share.D2014-10-29Director (Non-Executive)100k
Millner (Robert Dobson)Purchase at price 0.54 per share.D2014-05-01Director (Non-Executive)100k
Hampton (Miles Lawrence)D2014-01-30Former200k
Robinson (Peter Raymond)Purchase at price 0.51 per share.D2012-11-05Chairman of the Board100k
Millner (Robert Dobson)Purchase at price 0.52 per share.D2012-10-26Director (Non-Executive)100k
Masters (Gerard James)Purchase at price 0.42 per share.D2012-05-03Director (Independent)125k
Millner (Robert Dobson)Purchase at price 0.42 per share.D2012-05-02Director (Non-Executive)200k
Roche (Stephen Patrick)Purchase at price 0.29 per share.D2011-11-02Chief Executive Officer340k
Masters (Gerard James)Purchase at price 0.50 per share.D2010-11-25Director (Independent)93k
Hampton (Miles Lawrence)Purchase at price 0.44 per share.D2010-11-23Director (Independent)36.86k
Hampton (Miles Lawrence)Purchase at price 0.44 per share.D2010-11-22Director (Independent)54.81k
Sanguinetti (Peter F)D2010-08-31Secretary3.33k
Smith (Phil)D2010-08-31Divisional Officer215.41k
Roche (Stephen Patrick)Purchase at price 0.40 per share.D2010-05-11Chief Executive Officer220k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Australian Pharmaceutical Industries Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Australian Pharmaceutical Industries Limited

Here is the result of two systematic investment strategies applied to Australian Pharmaceutical Industries Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Australian Pharmaceutical Industries Limited

The following chart shows the equity curve of the two systematic investment strategies applied to Australian Pharmaceutical Industries Limited:

Australian Pharmaceutical Industries Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -12.01% on the backtest period.

Performance at glance

Performance

-12.01 %

Latent gain

-270.47 $

Invested capital

2251.3 $

Annualized return

-2.93 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Australian Pharmaceutical Industries Limited

This is the result of two momentum investment strategies applied to Australian Pharmaceutical Industries Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Australian Pharmaceutical Industries Limited

The following chart shows all the entries opened by the momentum investment system on Australian Pharmaceutical Industries Limited:

Australian Pharmaceutical Industries Limited momentum entries
  • The first momentum investment strategy would give -8.49% of return on Australian Pharmaceutical Industries Limited. That represents -488.13$ of latent gain with 5750.73$ of employed capital.
  • The second momentum investment strategy would give -8.43% of return on Australian Pharmaceutical Industries Limited. That represents -358.3$ of latent gain with 4250.12$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-8.49 %

Latent gain

-488.13 $

Invested capital

5750.73 $

Annualized return

7.67 %
Performance at glance (2Q Momentum)

Performance

-8.43 %

Latent gain

-358.3 $

Invested capital

4250.12 $

Annualized return

-2.33 %

Momentum equity curve on Australian Pharmaceutical Industries Limited

The following chart shows the equity curve of the two momentum strategies applied to Australian Pharmaceutical Industries Limited:

Australian Pharmaceutical Industries Limited momentum equity

Note: the dividends potentially given by Australian Pharmaceutical Industries Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Australian Pharmaceutical Industries Limited

The following chart shows the employed capital evolution of the two momentum strategies on Australian Pharmaceutical Industries Limited since the beginning:

Australian Pharmaceutical Industries Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Australian Pharmaceutical Industries Limited

Buy the dip entry openings on Australian Pharmaceutical Industries Limited

Australian Pharmaceutical Industries Limited

The performance achieved by the robo-advisor on Australian Pharmaceutical Industries Limited is 16.11%. That represents 40.29$ of latent gain with 250.03$ of employed capital. The following chart shows Australian Pharmaceutical Industries Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Australian Pharmaceutical Industries Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

16.11 %

Latent gain

40.29 $

Invested capital

250.03 $

Annualized return

7.67 %

Equity curve of the strategy applied to Australian Pharmaceutical Industries Limited

The following chart shows the result of the investment strategy applied to Australian Pharmaceutical Industries Limited:

Australian Pharmaceutical Industries Limited

Note: the dividends potentially given by Australian Pharmaceutical Industries Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Australian Pharmaceutical Industries Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on Australian Pharmaceutical Industries Limited:

Australian Pharmaceutical Industries Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Australian Pharmaceutical Industries Limited

In this section, I will compare the three previous investment strategies applied to Australian Pharmaceutical Industries Limited.

Equity curve comparison on Australian Pharmaceutical Industries Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Australian Pharmaceutical Industries Limited investment strategy comparison

Employed capital comparison on Australian Pharmaceutical Industries Limited

Australian Pharmaceutical Industries Limited investment comparison

Performance comparison on Australian Pharmaceutical Industries Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -12.01% -270.47$ 2251.3$ -2.93%
Momentum 1 quarter -8.49% -488.13$ 5750.73$ -2.2%
Momentum 2 quarters -8.43% -358.3$ 4250.12$ -2.33%
Non-directional 16.11% 40.29$ 250.03$ 7.67%
Annualized return comparison

Automatic investment

-2.93 %

Momentum 1Q

-2.33 %

Momentum 2Q

-2.33 %

Non-directional

7.67 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Australian Pharmaceutical Industries Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Australian Pharmaceutical Industries Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of Australian Pharmaceutical Industries Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Australian Pharmaceutical Industries Limited
Country Australia
City Camberwell
Address 250 Camberwell Road
Phone 61 3 8855 3000
Website www.api.net.au
FullTime employees
Industry Medical Distribution
Sector Healthcare
Exchange XASX
Ticker API.XASX
Market www2.asx.com.au

Australian Pharmaceutical Industries Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown